RemeGen Co., Ltd. (HKG:9995)
89.35
-0.60 (-0.67%)
May 15, 2026, 4:09 PM HKT
RemeGen Revenue
RemeGen had revenue of 656.21M CNY in the quarter ending March 31, 2026, with 24.76% growth. This brings the company's revenue in the last twelve months to 3.38B, up 76.81% year-over-year. In the year 2025, RemeGen had annual revenue of 3.25B with 89.36% growth.
Revenue (ttm)
3.38B CNY
Revenue Growth
+76.81%
P/S Ratio
16.96
Revenue / Employee
1.11M CNY
Employees
3,048
Market Cap
65.18B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.25B | 1.53B | 89.36% |
| Dec 31, 2024 | 1.72B | 633.91M | 58.54% |
| Dec 31, 2023 | 1.08B | 310.84M | 40.26% |
| Dec 31, 2022 | 772.11M | -651.79M | -45.78% |
| Dec 31, 2021 | 1.42B | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sino Biopharmaceutical | 35.43B |
| WuXi Biologics | 24.25B |
| 3SBio | 19.69B |
| Innovent Biologics | 14.51B |
| Genscript Biotech | 7.47B |
| Shanghai Henlius Biotech | 7.42B |
| Akeso | 3.40B |
| Shanghai Junshi Biosciences | 3.10B |
RemeGen News
- 4 months ago - AbbVie, RemeGen partner on experimental solid tumor treatment - Reuters
- 7 months ago - 2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China - PRNewsWire
- 9 months ago - RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries - PRNewsWire
- 10 months ago - RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA - PRNewsWire
- 11 months ago - PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement - Business Wire
- 11 months ago - RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis - PRNewsWire
- 1 year ago - RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China - PRNewsWire
- 1 year ago - Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis - PRNewsWire